All In Biotech

Drug Trial Radar · NCT06182358

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

Randomized Controlled Trial to Evaluate the Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Dec 27, 2023

Primary completion

Jan 27, 2025

Study completion Jan 27, 2025

Sponsor

Lead sponsor
Tarsus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.

Conditions

  • Demodex Blepharitis

Interventions

  • Lotilaner ophthalmic solution, 0.25%Drug

    XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days

  • Vehicle controlDrug

    Vehicle of XDEMVY administered topically twice a day for approximately 43 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of collarettes at Day 43Time frame: 43 days

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Site

    Cave Creek, Arizona

  • Site

    Long Beach, California

  • Vision Institute

    Colorado Springs, Colorado

  • Site

    Delray Beach, Florida

  • Site

    Indianapolis, Indiana

  • Site

    Pittsburg, Kansas

  • Site

    Louisville, Kentucky

  • Site

    Edina, Minnesota

  • Site

    Shelby, North Carolina

  • Site

    Fargo, North Dakota

  • Site

    Powell, Ohio

  • Site

    Cranberry Township, Pennsylvania

  • Site

    Memphis, Tennessee

  • Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.